Stifel raised the firm’s price target on HLS Therapeutics (HLTRF) to C$4.75 from C$4 and keeps a Hold rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential